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Abstract. The Forkhead box protein M1 (FOXM1) is a tran-
scription factor that plays a central role in the regulation of 
cell cycle, proliferation, DNA repair, and apoptosis. FOXM1 
is overexpressed in many human tumors and its upregulation 
has been linked to high proliferation rates and poor prognosis. 
We therefore studied the role of FOXM1 in B-lymphoblastic 
leukemia (B-ALL) in order to understand whether FOXM1 
could be a key target for leukemia therapy. RT-PCR and 
western blot analysis were carried out in a small cohort of 
pediatric B-ALL patients to evaluate FOXM1 levels. To assess 
its biological relevance, its expression was down-modulated 
by transient RNA interference in B-ALL cell lines (REH and 
NALM-6). Our results show that FOXM1 expression is higher 
in both B-ALL patients and cell lines when compared to PBMC 
or normal B-cells (CD19+) from healthy donors. Furthermore, 
blocking FOXM1 activity in two B-ALL cell lines, by either 
knockdown or treatment with the FOXM1 inhibitor thio-
strepton, causes significant decrease in their cell proliferation. 
This decrease in cell proliferation was coupled with both an 
induction of the G2/M cell cycle arrest and with a reduction 
in the S phase population. Finally, we noted how thiostrepton 
synergises with chemotherapeutic agents commonly used in 
B-ALL therapy, thus increasing their efficiency. Therefore 
our results suggest that FOXM1 is highly expressed in both 
patients and B-ALL cell lines, and that targeting FOXM1 
could be an attractive strategy for leukemia therapy and for 
overcoming drug resistance.
Introduction
FOXM1 is a member of the Forkhead family of transcription 
factors, previously known as Trident (in mouse), HFH-11 
(in human), WIN or INS-1 (in rat), MPP-2 (partial human 
cDNA) and FKHL-16 (1). FOXM1 is a potent oncogene whose 
expression is frequently upregulated during cancer initiation. 
FOXM1 expression increases at the entry of the S-phase of 
the cell cycle, remains stable during G2/M phase, before being 
degraded at the mitotic exit (2,3). FOXM1 also controls mitosis 
through the transcriptional regulation of mitotic regulatory 
genes, including PLK, Cyclin B1, Aurora A and B kinases (4), 
and in addition, it plays a major role in maintaining chromo-
some stability (2). FOXM1 has an important role in cell cycle 
progression and cell proliferation. As such, its expression levels 
correlate with the proliferative state of a cell. Not surpris-
ingly, FOXM1 is highly expressed in all embryonic tissues, 
particularly in proliferating cells of epithelial and mesen-
chymal origin (5). Its overexpression has also been detected 
in numerous human cancer cell lines and has been associated 
with the development and progression of many malignancies 
(6,7), with high cell proliferation rates, drug resistance (8-10) 
and poor prognosis in many cancer types (11-15).
B-lymphoblastic leukemia (B-ALL) is a malignant disorder 
which derives from clonal proliferation of lymphoid precur-
sors with arrested maturation. In recent years the role and 
involvement of FOXM1 in B-ALL and other hematological 
malignancies has become increasingly important. A previous 
study by Nakamura et al has examined the role of FOXM1 in 
cell proliferation in myeloid leukemia, showing its capability 
to promote cell cycle progression (16). Other studies have also 
demonstrated that FOXM1 downregulation causes the inhi-
bition of cell proliferation in B-lymphoma (17). A different 
report by Uddin et al has instead described the involvement of 
FOXM1 in B-cell lymphoma migration and invasion (18), and 
recently it has been pointed out that FOXM1 pathway could be 
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a potential therapeutic target in B cell malignancy (19,20). The 
role of FOXM1 as an oncogene and its upregulation in relapsed 
B-ALL patients (21), prompted us to investigate whether 
FOXM1 has a potential role in B-ALL cell proliferation, with 
particular focus on whether it can become a target that would 
increase the efficiency of chemotherapeutic treatment, and 
allow us to overcome drug resistance in this hematological 
malignancy.
Materials and methods
Primary leukemia cell cultures. The mRNA and protein 
samples of PBMC from healthy donors were obtained from 
cells separated by Ficoll-Paque centrifugation, while healthy 
B-cells (mainly CD19+) were obtained by cell sorting of bone 
marrows from healthy volunteers. Diagnostic RNA samples 
of bone marrow (BM) aspirates of B-leukaemic patients 
with a blast count of 80-95% were kindly allowed from the 
Cell Bank of the Dipartimento di Salute della Donna e del 
Bambino, University of Padova, Italy. B-ALL patient samples 
were obtained after informed consent following the tenets of 
the Declaration of Helsinki. The study was approved by the 
Italian Association of Pediatric Onco-Hematology (AIEOP). 
Written consent was obtained from participants. All analyzed 
B-ALL samples were obtained at the time of diagnosis before 
treatment, after Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) 
separation of mononuclear cells as described previously (22). 
The percentage of CD19+ cells ranged from 80 to 95%. Human 
B-leukemia cell lines, REH, SEM, MHH-CALL2, RS4;11 and 
NALM-6, were grown in RPMI-1640 medium (Gibco, Milan, 
Italy) all supplemented with 115 U/ml penicillin G (Gibco), 
115 µg/ml streptomycin (Invitrogen), 10% fetal bovine serum 
(Invitrogen), and maintained at 37˚C in a humidified atmo-
sphere with 5% CO2.
Quantitative real-time PCR. Total RNA was isolated from 
frozen cell pellets using the RNeasy Mini kit (Qiagen, UK) 
according to the manufacturer's instructions and RNA purity 
and concentration were determined by measuring the spectro-
photometric absorption at 260 nm and 280 nm on NanoDrop 
ND-1000. Total RNA (1 µg) was reverse transcribed into first 
strand cDNA using Superscript III first stand cDNA synthesis 
(Life Technologies, UK) Briefly, 1 µl of 50 µM oligo(dT)20 
and 1 µl of 10 mM dNTPs mix were added to the RNA before 
the volume was adjusted to 11 µl using RNase-free water. 
Samples were denaturated at 65˚C for 5 min and then quickly 
chilled on ice for 1 min. Subsequently, 1 µl of the reverse tran-
scriptase Superscript III (200 U/µl) was added, along with 1 µl 
0.1 M DTT, 1 µl RNaseOUT Recombinase Inhibitor and 
1X first stand buffer. The solution was incubated at 25˚C for 
5 min then heated at 50˚C for 50 min. The reaction was inacti-
vated by heating at 70˚C for 15 min. For real-time quantitative 
PCR, 1 µl of cDNA was used as template in a 24-µl reaction 
carried out with Power SYBR Green kit (Applied Biosystems, 
UK) with ABI 7800 system (Applied Biosystems). The mRNA 
levels of target genes were calculated relative to the expression 
of L19 mRNA levels using the ∆Ct method. Primers used: 
FOXM1-fwd, 5'-TGCAGCTAGGGATGTGAATCTTC-3'; 
FOXM1-rv,  5'-GGAGCCCAGTCCATCAGAACT-3'; 
CCNB1-fwd, 5'-CAGTTATGCAGCACCTGGCTAAG-3'; 
CCNB1-rv, 5'-TGTGGTAGAGTGCTGATCTTAGCAT-3'; 
AURKB-fwd, 5'-AGTGGGACACCCGACATC-3'; AURKB-rv, 
5'-GCCCAATCTCAAAGTCATCAATT-3'; L19-f wd, 
5'-GCGGAAGGGTACAGCCAAT-3'; L19-rv, 5'-GCAGCC 
GGCGCAAA-3'.
Western blot analysis. REH, SEM, MHH-CALL2, RS4;11 
and NALM-6, after experimental conditions, were collected, 
centrifuged, and washed two times with ice cold phosphate-
buffered saline (PBS). For western blot analysis cells were 
lysed as described previously (23). Proteins were resolved by 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS−PAGE) (using 7 or 10% acrylamide gels), transferred to 
PVDF Hybond-P membrane (GE Healthcare) and immuno-
blotted with primary antibodies against, FOXM1 (Santa Cruz, 
C-20), β-tubulin (Santa Cruz), Aurora B (Cell Signaling), 
Cyclin B1 (Santa Cruz). The membranes were washed four 
times with Tris-buffered saline and Tween-20 (TBS-T) for 
15 min prior to incubation with the respective peroxidise 
(HRP)-conjugated secondary antibody (Dako, Ely, UK), at 
1:2,000 dilution for 30 min at room temperature and again 
washed four times with TBST-T for 20 min. Protein were 
visualised using enhanced chemiluminescence (ECL) detec-
tion system (Perkin-Elmer, Seer Green, UK) with Amsterdam 
Hyperfilm ECL (GE Helthcare, Little Chalfont, UK) and signal 
was detected using the SRX-101A X-ray developer (Konica 
Minolta, Tokyo, Japan).
RNA interference with small interfering RNAs (siRNAs). For 
FOXM1 silencing, REH or NALM-6 cells were transiently 
transfected with siRNA SMARTpool reagents purchased from 
Thermo Scientific Dharmacon (Lafayette, CO, USA) using the 
transfection reagent Oligofectamine (Life Technologies, UK) 
according to the manufacturer's instructions. SMARTpool 
siRNAs used were: siRNA FOXM1 (l-009762-00) and 
the non-specific (NS) control siRNA, ON-TARGETplus 
Non-Targeting pool (D-001810-10) confirmed to have minimal 
targeting of known genes. All siRNA pools were resuspended 
to 20 µM in 1X siRNA buffer.
Annexin V assay. Surface exposure of phosphatidylserine on 
apoptotic cells was measured by flow cytometry with a Coulter 
Cytomics FC500 (Beckman Coulter) by adding Annexin V 
conjugated to fluorescein isothiocyanate (FITC) to cells 
according to the manufacturer's instructions (Annexin V Fluos, 
Roche Diagnostic). Simultaneously, the cells were stained with 
PI. Excitation was set at 488 nm, and the emission filters were 
at 525 and 585 nm, respectively, for FITC and PI.
Flow cytometric analysis of cell cycle distribution. For flow 
cytometric analysis of DNA content, 5x105 of REH, and 
NALM-6 cells were either treated with 0.5 and 1 µM of 
thiostrepton or knocked-down for FOXM1 and after 24, 48 
and 72 h of treatment or knockdown, cell cycle analysis was 
performed as previously described (24).
Drug combination studies. Cell proliferation was assessed by 
MTT (3-4,5-dimethylthiazol-2-yl-2,5-diphenyl tetrazolium 
bromide) assay after treatment. Equal concentrations of cells 
were plated in triplicate in a 96-well plate and incubated with 
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10 µl of MTT (Sigma-Aldrich, St. Louis, MO, USA) for 4 h. 
Absorbance was measured at 562 nm using Victor3™ 1420 
Multilabel Counter (Perkin-Elmer, Waltham, MA, USA). Cells 
were treated for 48 h using scalar dilutions of thiostrepton 
(Sigma-Aldrich), combined with cytarabine (Aractyn, Pfizer), 
daunorubicin (Pfizer), vincristine, dexamethasone (Sigma-
Aldrich). Thiostrepton was also added to drug solutions at 
fixed combination ratios. The effectiveness of various drug 
combinations was analyzed by Calcusyn Version 2.1 software 
(Biosoft). The combination index (CI) was calculated according 
to the Chou-Talalay method (25). A combination index of 1 
indicates an additive effect of the 2 drugs. Combination index 
values <1 indicate synergy, and combination index values >1 
indicate antagonism.
Statistical analysis. Results are presented as the mean ± SEM. 
The differences between different conditions were analyzed 
using the two-sided Student's t-test. P-values <0.05 were 
considered statistically significant.
Results
FOXM1 is overexpressed in B lymphoblastic leukaemic 
patients. To investigate whether FOXM1 regulates B lympho-
blastic leukemia (B-ALL) proliferation, we analyzed FOXM1 
mRNA levels in ten B-ALL pediatric patients comparing them 
to peripheral blood mononuclear cells (PBMC) from healthy 
donors. For these experiments, the mRNA was extracted from 
cell pellets of patients recruited at the time of diagnosis. The 
first two selected patients were characterized by chromosomal 
translocations at chromosome 12 and 21 [t(12;21)]; patients 3, 
4 and 5 carried the translocation between the chromosome 9 
and 22 [t(9;22)], whereas the other five patients were without 
translocations (Table I). As shown in Fig. 1A, FOXM1 mRNA 
Table I. Characteristics of patients samples.
B-ALL Gender Age at % of blast Cytogenetics
sample  diagnosis in BM 
  #1 F   6 82 9q22
  #2 M 16 91 9q22
  #3 F   5 77 12q21
  #4 M   3 90 12q21
  #5 F   3 63 12q21
  #6 F   8 97 Normal 
  #7 M   1 89 Normal 
  #8 F   8 90 Normal
  #9 M   4 90 Normal
#10 M   2 89 Normal
Figure 1. FOXM1 is higher expressed in B-ALL patients compared to healthy donors. (A-C) Basal FOXM1, AURKB and CCNB1 mRNA levels were analyzed 
in ten samples of B-ALL patients and compared to peripheral blood mononuclear cells (PBMC) of healthy donors by RT-qPCR. The results were normalised 
with L19 mRNA levels using the ∆∆Ct method. The median of threshold cycles (Ct) values was normalized to the median of Ct values of the L19 mRNA 
levels. Results are the average ± SD of three independent experiments in triplicate. (D) Cell lysates were obtained from ten B-ALL patients and analyzed for 
the expression of FOXM1 and its downstream target genes Cyclin B1 and Aurora B in comparison to PBMC.
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levels were significantly higher in patients when compared 
to the samples of healthy donors. Interestingly, a significant 
increment on Cyclin B1 and Aurora B mRNA levels, two 
genes whose expression is directly regulated by FOXM1 
was also observed (Fig. 1B and C). In addition to mRNA 
levels, protein expression was also examined by western blot 
analysis. As shown in Fig. 1D, the expression of FOXM1 and 
of its targets Aurora B and Cyclin B1 was generally higher 
in patients compared to healthy cells, confirming the upregu-
lated FOXM1 activity. Similar results were obtained when the 
mRNA or protein levels of B-ALL patients were compared to 
those of CD19-positive cells isolated from bone marrows of 
healthy donors (data not shown). Taken together, these data 
showed that the expression levels and activity of FOXM1 are 
increased in B-ALL patient samples when compared to healthy 
lymphocytes and normal B-cells, suggesting that FOXM1 
could plays a key function in supporting the cell proliferation 
of B-ALL.
FOXM1 is overexpressed in B-ALL cell lines. Next, we 
analyzed FOXM1 expression levels in five different B-ALL 
cell lines. More specifically, we quantified FOXM1 mRNA 
levels, at basal conditions, comparing five different B-ALL 
cell lines (REH, MHH-CALL2, SEM, NALM6, RS4;11) with 
mRNA samples of PBMC obtained from healthy donors. 
RT-qPCR analysis showed in Fig. 2A reveals that FOXM1 
mRNA levels were significantly higher in B-ALL cell lines 
when compared to normal lymphocytes. This pattern was 
again accompanied by increased transcriptional levels of 
Cyclin B1 and Aurora B (Fig. 2B and C). In agreement with 
the mRNA expression patterns, western blot analysis revealed 
that FOXM1 expression was generally higher in leukaemic 
cells compared to normal lymphocytes. This was again associ-
ated with Cyclin B1 and Aurora B upregulation in leukaemic 
cells (Fig. 2D). Similar results were obtained comparing the 
FOXM1 mRNA and protein expression of B-ALL cell lines 
with healthy CD19+ cells (data not shown).
FOXM1 silencing decreases cell proliferation in B-ALL cell 
lines and induces a G2/M cell cycle arrest. To test if FOXM1 
has a role in promoting B-ALL proliferation, we knocked 
down its expression in two B-ALL cell lines REH and 
NALM-6 using a specific FOXM1 siRNA pool and assessed 
the cell viability at 24, 48, and 72 h post-transfection. FOXM1 
silencing was confirmed by western blot and RT-qPCR 
analysis (Fig. 3A-D). Aurora B and Cyclin B1 protein levels 
were clearly downregulated in FOXM1-depleted NALM-6 
and REH cells compared to cells transfected with non-specific 
(NSC) control siRNA pool (Fig. 3A and B). Furthermore, in 
both REH and NALM-6 cell lines, RT-qPCR analysis revealed 
a significant decrease in Aurora B mRNA levels, although 
Cyclin B1 mRNA levels appeared significantly decreased only 
in REH and not in NALM-6 cells (Fig. 3C and D).
Cell proliferation analysis assessed by trypan blue exclu-
sion assay, revealed that upon FOXM1 depletion, there is a 
significant decrease in cell proliferation after 72 h of trans-
Figure 2. Expression of the FOXM1 is higher in B-ALL cell lines compared to healthy donors. (A-C) Basal FOXM1, AURKB and CCNB1 mRNA levels were 
analyzed in five B-ALL cell lines (REH, MHH-CALL2, SEM, RS4;11, NALM-6) and compared to peripheral blood mononuclear cells (PBMC) of healthy 
donors by RT-qPCR. Results are the average ± SD of three independent experiments in triplicate. (D) REH, MHH-CALL2, SEM, RS4;11, NALM-6 cell lysates 
were collected at basal conditions for subsequent western blot analysis for the indicated antibodies.
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fection in NALM-6 (Fig. 3E) and after 48 h in REH cells 
(Fig. 3F), suggesting that FOXM1 plays an important role in 
B-ALL cell proliferation. Trypan blue-negative population 
(live cells) was strongly decreased in cells that were silenced 
for FOXM1, with no significant changes in the levels of dead 
cells (trypan blue-positive) in NALM-6, and only with a slight 
increase in the percentage of dead cells in REH. These results 
pointed out that FOXM1 plays an important role in B-ALL 
cell proliferation.
To further analyze the role of FOXM1 on cell cycle progres-
sion in B-ALL, we analyzed the cell cycle phase distribution 
in NALM-6 and REH cells following FOXM1 knockdown. 
As shown in Fig. 4A and B, there was a significant increase 
on the percentage of cells in G2/M in both cell lines, and a 
corresponding decrease of cells in the S phase compared with 
non-specific (NSC) control cells, only in NALM-6 cells at 
72 h. The G2/M cell cycle arrest following FOXM1 silencing 
by siRNA is confirmed by the consistent downregulation of the 
expression of the G2/M regulators, Cyclin B1 and Aurora B 
(Fig. 4C and D). This further supports the role of FOXM1 
in cell cycle progression in B-ALL, particularly at the G2/M 
transition.
FOXM1 silencing reduces the expression of cell cycle 
regulators. We next evaluated if FOXM1 knockdown could 
modulate the expression of proteins involved in late phase cell 
cycle regulation. As depicted in Fig. 4, the FOXM1 silencing 
in both NALM-6 (Fig. 4C) and in REH cells (Fig. 4D), 
caused downregulation of cell cycle regulatory proteins such 
as Cyclin B1, Aurora B, Survivin, and Cdc25b, involved in 
mitotic progression. The expression of the S-phase promoting 
Cdc25a phosphatase, which plays a major role in G1/S progres-
sion, dephosphorylating Cdk2 and activating CDK2-cyclin E 
activity (26,27), was strongly reduced. Interestingly, both 
p27Kip1 and p21Cip/Waf1, were also downregulated. These two 
cyclin-dependent kinase inhibitor (CKI) proteins also play a 
Figure 3. FOXM1 knockdown in REH and NALM6 cells induces a significant decrease in cell proliferation. NALM-6 (A) and REH (B) were transfected with 
the siRNA FOXM1 and the non-specific (NSC) control siRNA. Western blot analysis and RT-qPCR confirmed the knockdown of endogenous FOXM1 and the 
reduced expression of Aurora B and Cyclin B1 in NALM-6 cells (A-C) and REH cells (B-D). Cell viability analysis, was performed by trypan blue assay, after 
72 h of transfection in NALM-6 (E) and after 48 h of transfection in REH (F). Data are presented as mean ± SD of three independent experiments. Statistical 
analysis was performed using Student's t-tests against the cells transfected with the non-specific (NS) control siRNA. *p≤0.05, **p≤0.01.
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role in the assembly of cyclin-CDK complexes. Altogether, 
these results indicate that FOXM1 is strongly involved in 
modulating the expression of cell cycle regulatory proteins at 
both the G1/S and at the G2/M cell cycle transitions.
Thiostrepton treatment induces G2/M arrest and decreased 
cell viability. To further confirm the role of FOXM1 on 
B-ALL cell proliferation, we treated cells with the thiazole 
ring containing antibiotic, thiostrepton, a well-established 
specific FOXM1 inhibitor (28,29). This drug causes growth 
inhibition in a small panel of B-ALL cell lines with GI50 in the 
micromolar and sub-micromolar range (GI50= 0.4-1.4 µM). In 
this context, we treated both NALM-6 and REH cell lines with 
two different concentrations of thiostrepton, 0.5 and 1 µM, 
respectively for 24, 48, and 72 h. Results show a significant 
reduction in cell viability, revealed by the considerable low 
numbers of trypan blue-negative cells in both NALM-6 and 
REH cell lines (Figs. 5A and 6A). Moreover, flow cytometric 
analysis carried out following different treatment times indi-
cates that thiostrepton induces apoptosis, demonstrated by the 
appearance of a large percentage of Annexin V-positive cells 
in both cell lines (Figs. 5B and 6B). Importantly, apoptosis 
occurs in a concentration- and time-dependent manner. In 
each assay, FOXM1 downregulation was confirmed by both 
Figure 4. FOXM1 downregulation in REH and NALM6 cells by a specific FOXM1 siRNA pool induces a G2/M cell cycle arrest. In NALM-6 (A) and REH 
cell (B) lines the endogenous FOXM1 expression was blocked by knockdown performed using Oligofectamine™ Transfection protocol. After 24, 48 and 72 h 
of knockdown, cell cycle analysis was performed to investigate the effect of FOXM1 inhibition in cell cycle-phase progression. Results are the average ± SD 
of three independent experiments in triplicate. Statistical analysis was performed using Student's t-tests against the cells transfected with the non-specific 
(NSC) siRNA. *p≤0.05, **p≤0.01, ***p≤0.001. Effect of FOXM1 knockdown on the expression of proteins involved in cell cycle regulation. In NALM-6 (C) and 
REH (D) cell lines the endogenous FOXM1 expression was blocked by knockdown and after 48 h, cells were collected, and protein extracts were subjected to 
western blot analysis for the indicated antibodies.
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Figure 5. FOXM1 inhibition in NALM-6 cells by thiostrepton treatment induces apoptosis. NALM-6 cells were treated with thiostrepton at the concentration 
of 0.5 or 1 µM, for 24, 48 and 72 h. Cell viability analysis was performed by trypan blue assay (A) whereas induction of apoptosis was assessed by flow 
cytometry after staining of the cells with Annexin V-FITC and propidium iodide (B). Dual staining permits discrimination between live cells (Annexin V-/PI-), 
early apoptotic cells (Annexin V+/PI-), late apoptotic cells (Annexin V+/PI+) and necrotic cells (Annexin V-/PI+). Western blot (C) and RT-qPCR analysis (D) 
confirmed that thiostrepton reduces FOXM1 expression. Data are presented as mean ± SD of three independent experiments. Statistical analysis was 
performed using Student's t-tests against the control sample (untreated). **p≤0.01, ***p≤0.001.
Figure 6. FOXM1 inhibition in REH cells by thiostrepton treatment induces apoptosis. REH cells were treated with thiostrepton at the concentration of 0.5 or 
1 µM, for 24, 48 and 72 h. Cell viability analysis was performed by trypan blue assay (A) whereas induction of apoptosis was assessed by flow cytometry after 
staining of the cells with Annexin V-FITC and propidium iodide (B). Dual staining permits discrimination between live cells (Annexin V-/PI-), early apoptotic 
cells (Annexin V+/PI-), late apoptotic cells (Annexin V+/PI+) and necrotic cells (Annexin V-/PI+). Western blot (C) and RT-qPCR analysis (D) confirmed 
that thiostrepton reduces FOXM1 expression. Data are presented as mean ± SD of three independent experiments. Statistical analysis was performed using 
Student's t-tests against the control sample (untreated). **p≤0.01, ***p≤0.001.
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Figure 7. FOXM1 downregulation in REH and NALM6 cells by thiostrepton treatment induces a G2/M cell cycle arrest. NALM-6 (A) and REH cell (B) lines 
were treated with the indicated concentration of thiostrepton. After 24, 48 and 72 h of treatment, cell cycle analysis was performed to investigate the effect 
of FOXM1 inhibition in cell cycle-phase progression. Results are the average ± SD of three independent experiments in triplicate. Statistical analysis was 
performed using Student's t-tests against the untreated cells. *p≤0.05, **p≤0.01, ***p≤0.001.
Figure 8. Effect of thiostrepton treatment alone and in combination with different chemotherapic drugs in NALM-6 cells (A). Cells were treated at the indi-
cated concentration and at fixed molar concentration ratio and viability was assessed by MTT-test after 48 h of incubation. Data are expressed as mean ± SEM 
of three independent experiments. (B) NALM-6 cells were knocked down for FOXM1 and after 48 h were further treated for 48 h with dexamethasone at the 
concentration of 1 µM. Cell viability was analyzed by flow cytometry after double staining of the cells with Annexin V-FITC and PI. Result are expressed 
as mean ± SD of three independent experiments. Statistical analysis was performed using Student's t-tests against the cells transfected with the non-specific 
(NSC) siRNA. *p≤0.01.
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western blot analysis (Figs. 5C and 6C) and by RT-qPCR 
(Figs. 5D and 6D). Note that in both cell lines, FOXM1 and 
its downstream target protein levels were decreased following 
thiostrepton treatment, in a manner similar to that observed for 
FOXM1 silencing.
We then analyzed the cell cycle phase distribution in REH 
and NALM-6 cells following treatment with both 0.5 and 
1 µM concentrations of thiostrepton at 24, 48, and 72 h. Results 
(Fig. 7A and B) show that similarly to FOXM1 knockdown 
experiments, thiostrepton treatment induces a cellular arrest 
at the G2/M cell cycle phase as well as a decrease of cells in 
the S phase.
Thiostrepton synergises with conventional chemotherapeutic 
agents to inhibit B-ALL proliferation. As FOXM1 down-
regulation led to a decrease on B-ALL cell proliferation, 
we next-tested if thiostrepton could be used in combination 
with the most commonly used chemotherapeutics in B-ALL 
treatment. To this end, four different B-ALL cell lines, two 
glucocorticoid-resistant (REH, SEM) and two glucocorticoid-
sensitive (NALM-6, RS4;11), were treated for 48 h with 
thiostrepton in combination with chemotherapeutic agents 
(i.e., dexamethasone, asparaginase, daunorubicin, vincristine 
and Ara-C) normally used to treat pediatric B-ALL patients. 
More specifically, thiostrepton was combined with different 
drugs at fixed molar combination ratios, and cell viability 
analyzed by MTT assay (Figs. 8A and 9A). As described 
above, thiostrepton has a significant cytotoxicity when used as 
single agent. Notably, when thiostrepton was used in combi-
nation with chemotherapic drugs, we observed a synergistic 
increase in the cytotoxicity as demonstrated by the values of 
combination index (CI) according to Chou and Talalay (25,30). 
As depicted in Table II, reporting CI values calculated at GI50, 
GI75 and GI90, in almost all cell lines tested, thiostrepton and 
chemotherapeutic drugs act in a synergistic fashion (CI<1). 
Our results therefore show that, in general, the pharmaco-
logical downregulation of FOXM1 caused by thiostrepton, can 
significantly increase the cell death induced by the treatment 
with conventional chemotherapeutic agents.
To prove the above further, we knocked down FOXM1 in 
REH and NALM-6 cells using siRNA, and then treated them 
with dexamethasone. After 48 h of treatment we analyzed cell 
viability by flow cytometry staining with Annexin V and prop-
idium iodide (PI). Results showed a significant decrease in 
cell viability after 48 h of treatment in FOXM1 silenced cells 
when compared to its controls, this was particularly noted in 
Figure 9. Effect of thiostrepton treatment alone and in combination with different chemotherapic drugs in REH cells (A). Cells were treated at the indicated 
concentration and at fixed molar concentration ratio and viability was assessed by MTT-test after 48 h of incubation. Data are expressed as mean ± SEM 
of three independent experiments. (B) REH cells were knocked down for FOXM1 and after 48 h were further treated for 48 h with dexamethasone at the 
concentration of 1 µM. Cell viability was analyzed by flow cytometry after double staining of the cells with Annexin V-FITC and PI. Result are expressed 
as mean ± SD of three independent experiments. Statistical analysis was performed using Student's t-tests against the cells transfected with the non-specific 
(NSC) siRNA. **p≤0.05.
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glucocorticoid resistant cells, indicating that FOXM1 can be 
an important therapeutic target for overcoming glucocorticoid 
resistance in B-ALL (Figs. 8B and 9B).
Discussion
FOXM1 is an important cell cycle regulator and plays a crucial 
role in tumorigenesis and its overexpression has been found in 
many different human cancers. However, very little is known 
about its function in hematological malignancies. Our aim 
was to investigate the role of FOXM1 in B-ALL, the most 
common pediatric leukemia. RT-PCR analysis performed on 
ten B-ALL patient samples showed that FOXM1 mRNA is 
highly overexpressed in comparison to FOXM1 mRNA from 
lymphocytes of healthy donors and more importantly also in 
comparison with normal B-cells (CD19+). These results are 
in excellent agreement with Buchner et al (20) who recently 
showed that FOXM1 is highly overexpressed in B-ALL irre-
spectively of different B-ALL subsets. It is important to note 
that our primers, irrespectively detect both B and C isoforms 
of FOXM1 which represent the active forms since the isoform 
FOXM1A, is not translated.
The pattern of FOXM1 is mirrored by Cyclin B1 and 
Aurora B, two G2/M phase regulators directly regulated by 
FOXM1. Immunoblot analysis also demonstrated similar over-
expression of FOXM1 and its downstream targets in samples 
from blast patients, suggesting that FOXM1 is also aberrantly 
overexpressed in B-ALL as in many other cancer types. In 
agreement, the five B-ALL cell lines analyzed also overex-
pressed FOXM1 and its downstream targets, confirming the 
results obtained in patients. Importantly, our study revealed 
that the FOXM1 depletion by siRNA causes a significant 
reduction in the proliferation rate of B-ALL cell lines, 
suggesting a role for FOXM1 in the oncogenesis of B-ALL. 
Moreover, FOXM1 silencing led to cell cycle arrest in G2/M, 
suggesting that FOXM1 promotes cell proliferation through 
cell-cycle modulation, previously reported by Nakamura et al 
in acute myeloid leukemia cells (16). Consistent with previous 
data (16), FOXM1 silencing in B-ALL cell lines led to a down-
regulation of proteins involved in the regulation of mitotic 
progression. We also showed that FOXM1 silencing is accom-
panied by a decrease on expression levels of p27Kip1 and p21Cip1/
Waf1 proteins, which are known to assemble different Cyclin/
Cdk complexes. p27Kip1 and p21Cip1/Waf1 proteins are phosphory-
lated by the Cdk2-cyclin E complex, to be recognized by the 
specificity subunits Skp2 and Cks1 of the SCF ubiquitin ligase 
complex, which targets them for ubiquitin-mediated protea-
some degradation (31-33). It could therefore be speculated that 
the noted decrease in their expression could reflect an acceler-
ated ubiquitinylation and subsequent degradation.
Thiostrepton is a thiazole antibiotic that inhibits the tran-
scriptional activity of FOXM1. It also downregulates FOXM1 
mRNA expression, since FOXM1 can positively auto-regulate 
its own transcription (28,34). Indeed, we found that both the 
mRNA and protein expression of FOXM1 were downregulated 
by thiostrepton in B-ALLs. In our study, we also found that 
thiostrepton remarkably reduces the cell viability of different 
B-ALL cell lines causing apoptosis in a concentration- and 
time-dependent manner, as well as inducing a G2/M arrest 
of the cell cycle, consistent with the result obtained with the 
siRNA-mediated knockdown of FOXM1.
The standard treatment option for newly diagnosed child-
hood B-ALL is predominantly chemotherapy. Patients that 
respond poorly to chemotherapy are predicted to undergo a 
future relapse. Understanding the biological mechanisms 
which underlie poor responsiveness is therefore crucial for 
the development of more effective therapies. Consistent with 
this, Bhatla et al have identified in a cohort of relapsed B-ALL 
pediatric patients a series of upregulated genes which also 
includes FOXM1 (21).
In light of these results we examined if combining thio-
strepton with the chemotherapeutics used in B-ALL therapy 
could increase their efficacy. Our results clearly indicate a 
strong synergistic effect (CI<1) between thiostrepton and 
drugs with different mechanisms of action in the four B-ALL 
cell lines tested. Our results are in good agreement with that 
reported by Uddin et al who reported a synergistic interac-
Table II. Combination index values (CI) in B-ALL cell lines 
treated with thiostrepton in combination with chemotherapic 
drugs.
  GI50b GI75b GI90b
Dauno (1:10)a 
 RS4;11 2.4 0.17 0.1
 SEM 0.27 0.28 0.35
 NALM-6 0.06 0.12 0.25
 REH 0.84 1.1 1.1
Ara-C (1:1)a
 RS4;11 0.07 0.2 0.006
 SEM 0.33 0.35 0.42
 NALM-6 0.0017 0.001 0.09
 REH 0.16 0.29 0.54
Dex (1:10)a
 RS4;11 0.10 0.9 8.0
 SEM 0.18 0.15 0.13
 NALM-6 0.8 0.044 0.24
 REH 1.1 0.97 0.85
Vcr (1:1,000a
 RS4;11 0.04 0.02 9.5
 SEM 1.1 0.75 0.6
 NALM-6 0.64 0.44 0.74
 REH 0.09 0.02 0.01
Asp (1:1)a
 RS4;11 0.5 0.2 0.1
 SEM 1.6 0.8 0.4
 NALM-6 0.10 0.13 0.5
 REH 1.3 0.05 0.15
aMolar ratio with thiostrepton. bGrowth inhibition determined after 
48 h of treatment by MTT-test. Ara-C, cytarabine; CI, combination 
index; Dex, dexamethasone; Dauno, daunorubicin; Vcr, vincristine. 
Synergy, additivity and antagonism are defined by a CI<1, CI=1 or 
CI>1, respectively.
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tion of thiostrepton with bortezomib in diffuse large B-cell 
lymphoma (18). It is also important to note that thiostrepton is 
able to partially reverse the glucocorticoid resistance in REH 
cells. These results were further confirmed, in a more specific 
way, in the same cell lines with silenced FOXM1 (Figs. 8B 
and 9B). Given that patients that respond poorly to glucocor-
ticoid therapy at diagnosis are usually predicted to undergo 
relapse in the future, our findings suggest that FOXM1 inhi-
bition could be a potential useful strategy in clinical therapy 
to optimize the efficacy of existing therapeutics for B-ALL, 
although further studies are needed to better understand the 
molecular mechanism(s) involved in these synergistic effects. 
Indeed, very recently Buchner et al (20) reported the efficacy 
of thiostrepton also in vivo in a mouse xenograft model of 
B-ALL. In conclusion, we show that FOXM1 has a role in 
both oncogenesis and the development of drug resistance in 
B-ALL, and the targeting of FOXM1 could be a useful means 
for treating B-ALL and for overcoming drug resistance.
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